We believe in science, advocacy & community, striving to make a real impact for those affected by rare diseases.
Redwood City, California
At Soleno Therapeutics, a Neurocrine Biosciences company, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more information, please visit soleno.life.
On-site · Canada
Deliver non-promotional education on Prader-Willi syndrome and approved therapies to patients, caregivers, and healthcare professionals. Coordinate engagement activities, support advocacy events, and collaborate cross-functionally to enhance disease understanding and treatment adherence.
